Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death (CHAGASICS)
CHronic Use of Amiodarone aGAinSt Implantable Cardioverter-defibrillator Therapy for Primary Prevention of Death in Patients With Chagas Cardiomyopathy Study (CHAGASICS)
Sponsor: Abbott Medical Devices
This NA trial investigates At Least 10 Points in Rassi Risk Score for Death and Chagas Cardiomyopathy and is currently ongoing. Abbott Medical Devices leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Sep 2021 — Sep 2023 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status NA
-
Nov 2019 — Jan 2021 [monthly]
Unknown Status NA
Status: Not Yet Recruiting → Unknown Status
-
Feb 2019 — Nov 2019 [monthly]
Not Yet Recruiting NA
-
Jun 2018 — Feb 2019 [monthly]
Not Yet Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
- InCor Heart Institute
- Ministry of Health, Brazil
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belo Horizonte, Brazil , Brasília, Brazil , Campinas, Brazil , Cuiabá, Brazil , Curitiba, Brazil , Fortaleza, Brazil , Goiânia, Brazil , Pouso Alegre, Brazil , Recife, Brazil , Ribeirão Preto, Brazil and 4 more locations